Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1222P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA plays a critical role in the spliceosome, the molecular machine responsible for removing introns from pre-messenger RNA during RNA splicing[3][5]. However, RNU6-1222P itself does not code for a functional RNA and is not transcribed or translated into an active product. Pseudogenes like RNU6-1222P are believed to result from the retrotransposition of RNA intermediates and serve as evolutionary remnants in the genome[2]. There is no evidence that RNU6-1222P has any biological activity, disease association, or relevance as a therapeutic or diagnostic target[1][2]. If you are seeking information about the functional U6 snRNA gene or spliceosomal RNAs in general, the main entry should be "U6 small nuclear RNA," not RNU6-1222P[3].
None (As a non-functional pseudogene, there is no mechanistic action associated with therapeutics[1].)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1222, pseudogene (RNU6-1222P).